10）Skogh E, Sjödin I, Josefsson M, Dahl ML. High correlation between serum and cerebrospinal fluid olanzapine concentrations in patients with schizophrenia or schizoaffective disorder medicating with oral olanzapine as the only antipsychotic drug. J Clin Psychopharmacol 2011; 31: 4-9.11）Josefsson M, Roman M, Skogh E, Dahl ML. Liquid chromatography/tandem mass spectrometry method for determination of olanzapine and N-desmethylolanzapine in human serum and cerebrospinal fluid. J Pharm Biomed Anal 2010; 53: 576-82.12）Flank J, Thackray J, Nielson D, August A, Schechter T, Alexander S, et al. Olanzapine for treatment and prevention of acute chemotherapy-induced vomiting in children: a retrospective, multi-center review. Pediatr Blood Cancer. 2015; 62: 496-501.13）Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S, et al. Efficacy and safety of olanzapine combined with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1301 phaseⅡ trial. Support Care Cancer. 2016; 24: 675-82.14）Naik RD, Vishnubhatla S, Singh V, Pillai AS, Dhawan D, Bakhshi S. Olanzapine for prevention of vomiting in children and adolescents receiving highly emetogenic chemotherapy: Investigator-initiated, randomized, open-label trial. J Clin Oncol 2020; 38: 3785-93.15）Yanai T, Iwasa S, Hashimoto H, Ohyanagi F, Takiguchi T, Takeda K, et al. A double-blind randomized phase Ⅱ dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. Int J Clin Oncol 2018; 23: 382-8.16）厚生労働省．「抗精神病薬ジプレキサ®錠（オランザピン）投与中の血糖値上昇による糖尿病性ケトアシドーシス及び糖尿病性昏睡について」.平成14年4月16日［https://www.pmda.go.jp/safety/info-services/drugs/calling-attention/esc-rsc/0004.html(accessed 2022-10-23)］1321）Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol 2017; 35: 3240-61.2）Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 2016; 27(Supplement 5): v119-v133. 3）Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M, et al. Olanzapine for the prevention of chemotherapy-induced nausea and vomiting. N Engl J Med 2016; 375: 134-42.4）Einhorn LH, Rapoport B, Navari RM, Herrstedt J, Brames MJ. 2016 updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following multiple-day chemotherapy, high-dose chemotherapy, and breakthrough nausea and vomiting. Support Care Cancer 2017; 25: 303-8.5）Hiemke C, Bergemann N, Clement HW, Conca A, Deckert J, Domschke K, et al. Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: Update 2017. Pharmacopsychiatry 2018; 51: 9-62.6）Lobo ED, Robertson-Plouch C, Quinlan T, Hong Q, Bergstrom RF. Oral olanzapine disposition in adolescents with schizophrenia or bipolar I disorder: A population pharmacokinetic model. Pediatr Drugs 2010; 12: 201-11.7）Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E, et al. Carriers of the UGT1A4 142T>G gene variant are predisposed to reduced olanzapine exposure - An impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 2010; 66: 465-74.8）Czerwensky F, Leucht S, Steimer W. CYP1A2*1D and *1F polymorphisms have a significant impact on olanzapine serum concentrations. Ther Drug Monit 2015; 37: 152-60.9）Miroshnichenko II, Pozhidaev IV, Ivanova SA, Baymeeva NV. Therapeutic drug monitoring of olanzapine and cytochrome P450 genotyping in nonsmoking subjects. Ther Drug Monit 2020; 42: 325-29.文 献
元のページ ../index.html#146